Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation
Pricing And Value Questions Dominate
Executive Summary
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
You may also be interested in...
Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
Scrip Asks… What Does 2020 Hold For Biopharma? Part 4: The Patient
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment
Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.